AGIOS PHARMACEUTICALS ($AGIO) posted quarterly earnings results for Q1 2026 on Wednesday, April 29th. The company reported earnings of -$1.69 per share, beating estimates of -$1.84 by $0.15. The company also reported revenue of $20,750,000, beating estimates of $13,918,920 by $6,831,080.
You can see Quiver Quantitative's $AGIO stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
AGIOS PHARMACEUTICALS Insider Trading Activity
AGIOS PHARMACEUTICALS insiders have traded $AGIO stock on the open market 19 times in the past 6 months. Of those trades, 0 have been purchases and 19 have been sales.
Here’s a breakdown of recent trading of $AGIO stock by insiders over the last 6 months:
- BRIAN GOFF (Chief Executive Officer) has made 0 purchases and 4 sales selling 37,771 shares for an estimated $1,168,514.
- SARAH GHEUENS (Chief Medical Officer) has made 0 purchases and 4 sales selling 8,526 shares for an estimated $297,673.
- TSVETA MILANOVA (Chief Commercial Officer) has made 0 purchases and 3 sales selling 9,066 shares for an estimated $270,253.
- JAMES WILLIAM BURNS (Chief Legal Officer) has made 0 purchases and 2 sales selling 6,212 shares for an estimated $193,276.
- CECILIA JONES (Chief Financial Officer) has made 0 purchases and 2 sales selling 6,073 shares for an estimated $188,451.
- KRISHNAN VISWANADHAN (Chief Corp Dev & Strategy) has made 0 purchases and 2 sales selling 5,918 shares for an estimated $184,967.
- THEODORE JAMES JR. WASHBURN (Principal Accounting Officer) sold 5,272 shares for an estimated $152,255
- DAVID SCADDEN sold 200 shares for an estimated $8,768
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.
AGIOS PHARMACEUTICALS Hedge Fund Activity
We have seen 133 institutional investors add shares of AGIOS PHARMACEUTICALS stock to their portfolio, and 117 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BELLEVUE GROUP AG removed 3,714,736 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $101,115,113
- PARADIGM BIOCAPITAL ADVISORS LP removed 2,673,555 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $72,774,167
- COMMODORE CAPITAL LP removed 2,338,287 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $63,648,172
- ARMISTICE CAPITAL, LLC added 2,272,000 shares (+297.4%) to their portfolio in Q4 2025, for an estimated $61,843,840
- MACQUARIE GROUP LTD removed 1,958,101 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $53,299,509
- WELLINGTON MANAGEMENT GROUP LLP removed 1,873,590 shares (-75.8%) from their portfolio in Q4 2025, for an estimated $50,999,119
- D. E. SHAW & CO., INC. added 1,469,437 shares (+399.6%) to their portfolio in Q4 2025, for an estimated $39,998,075
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.
AGIOS PHARMACEUTICALS Congressional Stock Trading
Members of Congress have traded $AGIO stock 2 times in the past 6 months. Of those trades, 2 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $AGIO stock by members of Congress over the last 6 months:
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 2 times. They made 2 purchases worth up to $30,000 on 03/03, 12/11 and 0 sales.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API.
AGIOS PHARMACEUTICALS Analyst Ratings
Wall Street analysts have issued reports on $AGIO in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Leerink Partners issued a "Outperform" rating on 12/26/2025
- B of A Securities issued a "Buy" rating on 12/24/2025
- Citigroup issued a "Buy" rating on 11/26/2025
- Truist Securities issued a "Buy" rating on 11/24/2025
- HC Wainwright & Co. issued a "Buy" rating on 11/20/2025
To track analyst ratings and price targets for AGIOS PHARMACEUTICALS, check out Quiver Quantitative's $AGIO forecast page.
AGIOS PHARMACEUTICALS Price Targets
Multiple analysts have issued price targets for $AGIO recently. We have seen 8 analysts offer price targets for $AGIO in the last 6 months, with a median target of $39.0.
Here are some recent targets:
- Greg Harrison from B of A Securities set a target price of $41.0 on 04/21/2026
- Emily Bodnar from HC Wainwright & Co. set a target price of $50.0 on 04/20/2026
- Tessa Romero from JP Morgan set a target price of $36.0 on 04/06/2026
- Salveen Richter from Goldman Sachs set a target price of $32.0 on 04/01/2026
- Samantha Semenkow from Citigroup set a target price of $46.0 on 03/05/2026
- Andrew Berens from Leerink Partners set a target price of $40.0 on 12/26/2025
- Gregory Renza from Truist Securities set a target price of $38.0 on 12/24/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
